1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Aug 2024
Admin
News Article

Altamira Medica Extends Bentrio Distribution Agreement with Pharma Nordic

Altamira Medica extends Bentrio distribution agreement with Pharma Nordic to include Sweden and Denmark

Overview

Altamira Therapeutics Ltd. (Altamira) announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (Pharma Nordic) to extend the territory covered by their exclusive distribution agreement for Bentrio to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.

Words from the CEO: Altamira Medica

“We have been very pleased and impressed by Pharma Nordic’s market launch activities and success in Norway,” commented Thomas Meyer, Altamira Medica’s chairman and CEO.
“It is therefore of mutual interest to expand in a next step the geographical scope of our collaboration to include Sweden and Denmark. We look forward to bringing Bentrio to patients in these two other countries and to continuing to build the product together with Pharma Nordic into one of the leading brands for allergic rhinitis management in Scandinavia.”

Words from the CEO: Pharma Nordic

“We received very favourable responses to Bentrio from members of the medical community and allergic rhinitis sufferers in Norway, showing a clear need for effective and safe treatment alternatives” stated Bent Andreassen, CEO of Pharma Nordic.
“With its drug-free and preservative-free formulation, as well as strong data on efficacy and tolerability, Bentrio is uniquely positioned to address patients’ unmet needs. We are very excited to continue the roll-out in Norway and to take Bentrio into the Swedish and Danish markets, which share many things in common, notably a passion for innovative health care products.”

About the drug: Bentrio

Bentrio is an “over the counter” drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses.
Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa.
This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge.
The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one (NASAR study) enrolled 100 patients suffering from seasonal allergic rhinitis.
In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 times per day.
The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001).
In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment.

Altamira Therapeutics work for Peptide-based Nanoparticle Technologies

Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore/SemaPhore platforms).
The company currently has two flagship siRNA programmes using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept.

About Pharma Nordic AS

Pharma Nordic AS, Aalsund, Norway holds licenses in the Nordic countries on over-the-counter (OTC) medicines and medical-technical equipment that are already on the world market or are about to be launched on markets outside the Nordic countries.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!